Osteodystrophy in chronic liver diseases

Internal and Emergency Medicine

Volumn 8, Issue 5, 2013, Pages 377-388

  Mansueto, Pasquale ^a,b   Carroccio, Antonio ^a   Seidita, Aurelio ^a   Di Fede, Gaetana ^a   Craxì, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Bisphosphonates; Chronic liver disease; Osteomalacia; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

BONE DENSITY; CHRONIC DISEASE; HUMAN; LIVER DISEASE; METABOLIC BONE DISEASE; OSTEOMALACIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; QUALITY OF LIFE; REVIEW; RISK FACTOR;

BONE DENSITY; BONE DISEASES, METABOLIC; CHRONIC DISEASE; DIPHOSPHONATES; HUMANS; LIVER DISEASES; OSTEOMALACIA; OSTEOPOROSIS; QUALITY OF LIFE; RISK FACTORS;

EID: 84880511160     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-012-0753-5     Document Type: Review

References (51)

1. Sanchez AJ, Aranda-Michel J (2006) Liver disease and osteoporosis. Nutr Clin Pract 21: 273-278.
2. Pappa HM, Bern E, Kamin D, Grand RJ (2008) Vitamin D status in gastrointestinal and liver disease. Curr Opin Gastroenterol 24: 176-183.
3. Arteh J, Narra S, Nair S (2010) Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 55: 2624-2628.
4. Dontas IA, Yiannakopoulos CK (2007) Risk factors and prevention of osteoporosis-related fractures. J Musculoskelet Neuronal Interact 7: 268-272.
5. Collier J (2007) Bone disorders in chronic liver disease. Hepatology 46: 1271-1278.
6. Stellon AJ, Webb A, Compston J, Williams R (1987) Low bone turnover state in primary biliary cirrhosis. Hepatology 7: 137-142.
7. Handelsman DJ, Strasser S, McDonald JA, Conway AJ, McCaughan GW (1995) Hypothalamic-pituitary-testicular function in end-stage non-alcoholic liver disease before and after liver transplant. Clin Endocrinol 43: 331-337.
8. Bell H, Raknerud N, Falch JA, Haug E (1995) Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non alcoholic cirrhosis. Eur J Endocrinol 132: 444-449.
9. Williams FM, Spector TD (2007) The genetics of osteoporosis. Acta Rheumatol Port 32: 231-240.
10. Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Mühllechner P, Habior A, Graziadei I, Vogel W, Tilg H (2005) The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 43: 973-983.
11. Gallego-Rojo FJ, Gonzalez-Calvin JL, Muñoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D (1998) Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 28: 695-699.
12. Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ (2006) Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 166: 1256-1261.
13. Smith DL, Shire NJ, Watts NB, Schmitter T, Szabo G, Zucker SD (2006) Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease. J Clin Densitom 9: 105-113.
14. Ruiz-Gaspa S, Martinez-Ferrer A, Enjuanes A, Peris P, Martinez de Osaba MJ, Alvarez L, Monegal A, Combalia A, Guanabens N, Pares A (2010) High bilirubin reduces cell survival and differentiation of primary human osteoblasts. Is this effect applicable to the serum of chronic cholestatic patients? J Hepatol 52: s214-s215.
15. Guañabens N, Cerdá D, Monegal A, Pons F, Caballería L, Peris P, Parés A (2010) Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 138: 2348-2356.
16. Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD (2001) Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 35: 316-323.
17. Mounach A, Ouzzif Z, Wariaghli G, Achemlal L, Benbaghdadi I, Aouragh A, Bezza A, El Maghraoui A (2008) Primary biliary cirrhosis and osteoporosis: a case-control study. J Bone Miner Metab 26: 379-384.
18. Solaymani-Dodaran M, Card TR, Aithal GP, West J (2006) Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology 131: 1752-1757.
19. Benetti A, Crosignani A, Varenna M, Giussani CS, Allocca M, Zuin M, Podda M, Battezzati PM (2008) Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study. J Clin Gastroenterol 42: 306-311.
20. Guañabens N, Parés A, Ros I, Caballería L, Pons F, Vidal S, Monegal A, Peris P, Rodés J (2005) Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 42: 573-577.
21. Angulo P, Therneau TM, Jorgensen A, DeSotel CK, Egan KS, Dickson ER, Hay JE, Lindor KD (1998) Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol 29: 729-735.
22. Angulo P, Grandison GA, Fong DG, Keach JC, Lindor KD, Bjornsson E, Koch A (2011) Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 140: 180-188.
23. Guichelaar MM, Malinchoc M, Sibonga J, Clarke BL, Hay JE (2002) Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology 36: 895-903.
24. Valenti L, Varenna M, Fracanzani AL, Rossi V, Fargion S, Sinigaglia L (2009) Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int 20: 549-555.
25. Loria I, Albanese C, Giusto M, Galtieri PA, Giannelli V, Lucidi C, Di Menna S, Pirazzi C, Corradini SG, Mennini G, Rossi M, Berloco P, Merli M (2010) Bone disorders in patients with chronic liver disease awaiting liver transplantation. Transplant Proc 42: 1191-1193.
26. Yenice N, Gümrah M, Mehtap O, Kozan A, Türkmen S (2006) Assessment of bone metabolism and mineral density in chronic viral hepatitis. Turk J Gastroenterol 17: 260-266.
27. Schiefke I, Fach A, Wiedmann M, Aretin AV, Schenker E, Borte G, Wiese M, Moessner J (2005) Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 11: 1843-1847.
28. Solís-Herruzo JA, Castellano G, Fernández I, Muñoz R, Hawkins F (2000) Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 33: 812-817.
29. Hofmann WP, Kronenberger B, Bojunga J, Stamm B, Herrmann E, Bücker A, Mihm U, von Wagner M, Zeuzem S, Sarrazin C (2008) Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy. J Viral Hepat 15: 790-796.
30. Diamond T, Stiel D, Lunzer M, Wilkinson M, Posen S (1989) Ethanol reduces bone formation and may cause osteoporosis. Am J Med 86: 282-288.
31. Peris P, Guañabens N, Parés A, Pons F, del Rio L, Monegal A, Surís X, Caballería J, Rodés J, Muñoz-Gómez J (1995) Vertebral fractures and osteopenia in chronic alcoholic patients. Calcif Tissue Int 57: 111-114.
32. Meys E, Fontanges E, Fourcade N, Thomasson A, Pouyet M, Del-mas PD (1994) Bone loss after orthotopic liver transplant. Am J Med 97: 445-450.
33. Guichelaar MM, Schmoll J, Malinchoc M, Hay JE (2007) Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors. Hepatology 46: 1198-1207.
34. Guichelaar MM, Kendall R, Malinchoc M, Hay JE (2006) Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 12: 1390-1402.
35. Encke J, Uhl W, Stremmel W, Sauer P (2004) Immunosuppression and modulation in liver transplant. Nephrol Dial Transplant 19(Suppl 4): iv22-iv25.
36. Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C, Otto G, Lange R, Theilmann L, Zimmerman R, Pritsch M, Ziegler R (2001) Frequency and predictors of osteoporotic fractures after cardiac or liver transplant: a follow-up study. Lancet 357: 342-347.
37. Collier JD, Ninkovic M, Compston JE (2002) Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 50(Suppl 1): i1-i9.
38. Leslie WD, Bernstein CN, American Gastroenterological Association Clinical Practice Committee (2003) AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 125: 941-966.
39. Grey A (2007) Emerging pharmacologic therapies for osteoporosis. Expert Opin Emerg Drugs 12: 493-508.
40. Crawford BA, Labio ED, Strasser SI, McCaughan GW (2006) Vitamin D replacement for cirrhosis related bone disease. Nat Clin Pract Gastroenterol Hepatol 3: 689-699.
41. Guañabens N, Parés A, Ros I, Alvarez L, Pons F, Caballería L, Monegal A, Martínez de Osaba MJ, Roca M, Peris P, Rodés J (2003) Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 98: 2268-2274.
42. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Ikeda K, Kumada H (2008) Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease. J Med Virol 80: 1302-1307.
43. Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, Lindor KD (2005) Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 42: 762-771.
44. Guanabens N, Cerda D, Monegal A, Muxi A, Caballeria L, Peris P (2010) Monthly ibandronate vs. weekly alendronate in the treatment of osteoporosis associated with primary biliary cirrhosis: similar efficacy but different adherence. J Hepatol 52: S79.
45. Floreani A, Carderi I, Ferrara F, Rizzotto ER, Luisetto G, Canozzi V, Baldo V (2007) A 4 year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis. Dig Liver Dis 39: 544-548.
46. Owens G, Jackson R, Lewiecki EM (2007) An integrated approach: bisphosphonate management for the treatment of osteoporosis. Am J Manag Care 13(Suppl 11): S290-S308.
47. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (2007) A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29: 1548-1558.
48. Boone RH, Cheung AM, Girlan LM, Heathcote EJ (2006) Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci 51: 1103-1112.
49. Levy C, Harnois DM, Angulo P, Jorgensen R, Lindor KD (2005) Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int 25: 117-121.
50. Blake GM, Fogelman I (2006) Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficacy. Clin Interv Aging 1: 367-375.
51. Girotra M, Rubin MR, Bilezikian JP (2006) The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 7: 113-121.